AudioEye (NASDAQ:AEYE) announced Tuesday its 40th consecutive period of record revenue, signaling that the global push for digital accessibility continues to fuel the company’s expansion.
BriaCell Therapeutics Corp. (NASDAQ:BCTX) announced Tuesday that the first patient in its Bria-OTS trial achieved an 11-month sustained complete resolution of a lung metastasis, providing a significant early validation for the company’s personalized "off-the-shelf" immunotherapy platform.
U.S. Bancorp (NYSE:USB) agreed to acquire financial services firm BTIG in a deal valued at as much as $1 billion, a strategic move by the fifth-largest U.S. bank to aggressively expand its footprint in investment banking and institutional trading.
BNY (NYSE:BNY) reported fourth-quarter 2025 results that surpassed Wall Street’s expectations, fueled by a surge in fee-based income and a record expansion of its custody empire.
Fortress Biotech Inc. (Nasdaq: FBIO) and its majority-owned subsidiary, Cyprium Therapeutics, secured a historic regulatory victory Tuesday as the U.S. Food and Drug Administration approved ZYCUBO® (copper histidinate) as the first-ever treatment for Menkes disease.
Concentrix Corporation (NASDAQ:CNXC) reported fourth-quarter and full-year 2025 results that beat its own revenue targets, even as a massive non-cash impairment charge forced the company into a GAAP operating loss.
NeuroPace (NASDAQ:NPCE) crossed a major financial threshold in 2025, reporting preliminary full-year revenue of approximately $100 million as its brain-responsive neurostimulation technology gains traction as a standard of care for drug-resistant epilepsy.
Cardiol Therapeutics (NASDAQ:CRDL) announced Tuesday that it has surpassed 50% patient enrollment in its pivotal Phase III MAVERIC trial, a major step toward bringing the first non-immunosuppressive oral therapy to patients suffering from recurrent pericarditis.
JPMorgan Chase & Co. (NYSE:JPM) kicked off the 2026 earnings season on Tuesday with a complex set of results that highlighted a growing divide between its "Main Street" lending and "Wall Street" trading arms.
AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo have announced the first patient has been dosed in the TROPION-Lung17 Phase 3 trial, a landmark study that marks the first time an antibody-drug conjugate (ADC) is being evaluated using a prospective, AI-powered biomarker in lung cancer.
Sight Sciences (NASDAQ:SGHT), a leader in interventional eyecare technologies, released preliminary fourth-quarter 2025 results on Jan. 13, showing a return to growth driven by its interventional dry eye business.
Treace Medical Concepts (NASDAQ:TMCI) shares are under scrutiny after the bunion-correction specialist reported preliminary fourth-quarter revenue that reflected a nearly double-digit decline.
